Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

0.6232
+0.01081.76%
Post-market: 0.63500.0118+1.89%19:49 EDT
Volume:217.50K
Turnover:133.63K
Market Cap:3.97M
PE:-0.15
High:0.6333
Open:0.5941
Low:0.5941
Close:0.6124
Loading ...

Dermata Therapeutics Inc trading halted, news pending

TIPRANKS
·
5 hours ago

Dermata Therapeutics Announces 1:10 Reverse Stock Split Effective August 1, 2025

Reuters
·
30 Jul

Dermata Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
16 Jul

Dermata Therapeutics receives notice of grant of Australian patent

TIPRANKS
·
08 Jul

Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Reuters
·
08 Jul

Dermata Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
08 Jul

Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments

Reuters
·
11 Jun

Dermata Therapeutics Inc. Appoints Baker Tilly as New Certifying Accountant Following Merger

Reuters
·
06 Jun

Dermata Therapeutics Is Maintained at Buy by Maxim Group

Dow Jones
·
21 May

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

TIPRANKS
·
21 May

BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing

Reuters
·
21 May

Dermata Therapeutics Inc. Announces Initiation of Drug Manufacturing for XYNGARI™ Phase 3 STAR-2 Trial, Set to Begin in Q4 2025

Reuters
·
21 May

Dermata Faces Nasdaq Delisting Risk Over Bid Price

TIPRANKS
·
17 May

Dermata Reports Positive Phase 3 Trial Results

TIPRANKS
·
14 May

Dermata Therapeutics Announces Positive Phase 3 Trial Results, Reports $6.6M Cash Increase in Q1 2025

Reuters
·
14 May

Press Release: California Water Service Group Reports First Quarter 2025 Results

Dow Jones
·
01 May

Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks

TIPRANKS
·
15 Apr

BRIEF-Dermata Therapeutics Inc - Announces Topline Results From Phase 3 Trial Of Xyngari - SEC Filing

Reuters
·
15 Apr

Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages

TIPRANKS
·
29 Mar

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

ACCESS Newswire
·
28 Mar